trending Market Intelligence /marketintelligence/en/news-insights/trending/frl4093EbmrhBoiCImYg_A2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Cosmo, RedHill Biopharma enter strategic collaboration for US rights to Aemcolo

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Cosmo, RedHill Biopharma enter strategic collaboration for US rights to Aemcolo

Cosmo Pharmaceuticals NV and RedHill Biopharma Ltd. have entered into an exclusive license agreement for the U.S. rights to traveler's diarrhea drug Aemcolo.

As part of the deal, the Dublin-based pharmaceutical company will invest $36.3 million in RedHill at $7 per American depositary share, or ADS.

Tel-Aviv, Israel-based RedHill will have exclusive U.S. rights to commercialize Aemcolo, and Cosmo will be the exclusive supplier of the drug. The license agreement also provides for granting certain rights to RedHill for the potential development of additional uses for Aemcolo, as well as arrangements related to other potential products of Cosmo.

RedHill entered into the collaboration primarily to prepare for the launch of its oral capsule Talicia to treat H. pylori infection, the company said in an Oct. 18 press release.

In addition to the $36.3 million investment, RedHill will issue 1,714,286 ADSs valued at about $12 million to Cosmo as an up-front payment for the rights granted under the Aemcolo license. The Israeli pharmaceutical company will also pay Cosmo a royalty percentage on net sales of the drug in the U.S.

Under the license agreement, Cosmo is also eligible for potential regulatory and commercial milestone payments of up to $100 million and is entitled to nominate one member to RedHill's board.